How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials

Citation
Lee MMY, Petrie MC, McMurray JJV, Sattar N. Arterioscler Thromb Vasc Biol 2020;40:506–22.